FIZE Medical, a leader in smart fluid management solutions for critically ill patients, today announced the launch of a retrospective study analyzing data from 5,000 ICU patients to evaluate how continuous real-time urine-output monitoring via the FIZE kUO® platform can enhance patient’s hemodynamic status assessment and decision-making at the bedside.

In critically ill patients, maintaining hemodynamic stability, the body’s ability to deliver oxygen and nutrients effectively to vital organs, is central to survival. When that balance is disrupted, patients are at risk of shock, organ failure, and increased mortality. Yet in most ICUs, key elements of hemodynamic assessment still rely on intermittent measurements that can miss early signs of deterioration.

By continuously capturing renal function patterns, the study aims to demonstrate how FIZE kUO® can provide data for early signs of instability that are often missed by intermittent measurements. It will further evaluate correlations between FIZE kUO® use and patient outcomes, including the incidence of acute kidney injury (AKI) and fluid imbalance.

“Kidney function is one of the key indicators of physiological stability in ICU patients” said Prof. Phillip Levin, Director of the Dept of Intensive Care at Shaare Zedek Medical Center. “Real-time accurate data on kidney function, possibly from measurements beyond hourly urine output, may help clinicians identify physiological derangements earlier and support more data-driven decision-making.”

”Our goal is to make smart hemodynamic management fully data-driven and seamlessly integrated into clinical workflow,” said Dror Zemer, CEO of FIZE Medical. “This study is an important step toward giving clinicians continuous, actionable, real-time insights at the bedside to support faster, data-driven decisions for their patients.”

FIZE Medical’s flagship solution, the FIZE kUO®, is commercially deployed in leading hospitals worldwide, where it has monitored more than 20,000 patients.